dtx

The current version of PEAR-004, the company's digital therapeutic for schizophrenia
By  Jonah Comstock 01:59 pm January 13, 2021
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture. The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
A product shot of the Bold Health app
By  Dave Muoio 03:16 pm December 14, 2020
Bold Health, a London-based company developing digital therapeutics for gastrointestinal conditions, is backing a new University of Pennsylvania-led study that will directly compare the company's cognitive behavior therapy (CBT) app for irritable bowel syndrome (IBS) to Headspace's consumer mindfulness and meditation app. According to a clinicaltrials.gov listing spotted by Exits & Outcomes,...
Three reSET app screen examples
By  Dave Muoio 12:14 pm December 8, 2020
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2. The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
Joe Biden discussing COVID-19

 (Photo by Joshua Roberts/Getty Images)

By  Laura Lovett 12:01 pm November 10, 2020
Now that the election has been called in favor of now President-elect Joe Biden, the medical community has poured out offering congratulations, suggestions and predictions. The bulk of the organizations are towing a nonpartisan line, pledging to work with the new administration, but remaining shy of political backing.  Innovation  One such organization is the American Telemedicine Association....
Images of the NightWare app on Apple Watches
By  Dave Muoio 02:47 pm November 9, 2020
The FDA granted Minneapolis-based NightWare a De Novo clearance on Friday for its Apple Watch and iPhone app designed to improve the sleep quality of those experiencing nightmare disorder and nightmares related to PTSD. The digital therapeutic – which received breakthrough designation from the agency last year – uses the Watch's sensors to track the heart rate and movement of users as they sleep...
By  Dave Muoio 01:55 pm November 5, 2020
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period. The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...
By  Dave Muoio 04:53 pm September 11, 2020
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said. Employing cognitive and neurobehavioral...
By  Dave Muoio 01:40 pm August 31, 2020
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
By  Aline Noizet 02:16 am April 29, 2020
Dr. Morcillo is the director of internal medicine Hospital Cima Sanitas in Barcelona and the medical director of Sanitas digital hospital. He is an active advocate and user of digital technologies in his daily practice. He will join the HIMSS & Health 2.0 European Digital Event (7-11 September 2020) as an expert in the session on digital therapeutics. The below Q&A has been edited for...
By  Dave Muoio 06:00 am April 22, 2020
Less than a week after FDA opened the faucet for digital health products treating psychiatric conditions during the COVID-19 health crisis, Akili has fast-tracked and released its approval-pending digital therapeutic for children with ADHD. Now known as Endeavor and flanked by a symptom tracker and caretaker support line, the video game-like app will be provided at no cost for a limited time to...